Alpha 2.0
Login Register
» Authors » K Westinga

K Westinga

Explore the profile of K Westinga including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 83
Followers 0
Related Specialties
General Surgery
Biochemistry
Oncology
Top 10 Co-Authors
E Spierings
L E Franssen
J Kuball
R Oostvogels
T Mutis
H M Lokhorst
I Slaper-Cortenbach
E Goulmy
H J Lamb
E Kneppers
Published In
Bone Marrow Transplant
J Biol Chem
Neth Heart J
Leukemia
Affiliations
Soon will be listed here.
Recent Articles
1.
Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT
Stuut A, Nijssen C, van der Wagen L, van Rhenen A, Daenen L, Janssen A, et al.
Bone Marrow Transplant . 2025 Mar; PMID: 40089614
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) aims to cure patients without inducing severe graft-versus-host disease (GVHD) or relapse. In prospective studies of mostly pediatric patients with haploidentical donors, ex vivo...
2.
Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia
Mann I, Tseng C, Rodrigo S, Koudstaal S, van Ramshorst J, Beeres S, et al.
Neth Heart J . 2018 Dec; 27(2):81-92. PMID: 30569306
Background: It has been suggested that bone marrow cell injection may have beneficial effects in patients with chronic ischaemic heart disease. However, previous trials have led to discrepant results of...
3.
A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma
Franssen L, Roeven M, Hobo W, Doorn R, Oostvogels R, Falkenburg J, et al.
Bone Marrow Transplant . 2017 Jun; 52(10):1378-1383. PMID: 28581468
Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte infusions (DLI) is the only curative option for several hematological malignancies. Unfortunately, allo-SCT is often associated with GvHD, and patients...
4.
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
Oostvogels R, Kneppers E, Minnema M, Doorn R, Franssen L, Aarts T, et al.
Bone Marrow Transplant . 2016 Nov; 52(2):228-237. PMID: 27841858
Donor lymphocyte infusions (DLI) can induce durable remissions in multiple myeloma (MM) patients, but this occurs rather infrequently. As the graft-versus-tumor (GvT) effect of DLI depends on the presence of...
5.
Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells
Te Boome L, Mansilla C, van der Wagen L, Lindemans C, Petersen E, Spierings E, et al.
Leukemia . 2015 Apr; 29(9):1839-46. PMID: 25836589
We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs)....
6.
Molecular and Biochemical Characterization of Rat epsilon -N-Trimethyllysine Hydroxylase, the First Enzyme of Carnitine Biosynthesis
Vaz F, Ofman R, Westinga K, Back J, Wanders R
J Biol Chem . 2001 Jun; 276(36):33512-7. PMID: 11431483
epsilon-N-Trimethyllysine hydroxylase (EC ) is the first enzyme in the biosynthetic pathway of l-carnitine and catalyzes the formation of beta-hydroxy-N-epsilon-trimethyllysine from epsilon-N-trimethyllysine, a reaction dependent on alpha-ketoglutarate, Fe(2+), and oxygen....